Ifosfamide
Based on 10 publication(s) in Google Scholar
Ifosfamide is a CNS-penetrant alkylating chemotherapeutic agent with activity against a wide range of tumors.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity : 99.89%
- CAS No.: 3778-73-2
- 화학식: C7H15Cl2N2O2P
- 분자량:261.09
-
보관:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
용액&용해도
- 순도&문서
- References
-
Help & FAQs
-
HY-17420
CyclophosphamideAlkylating Agent -
HY-17394
CisplatinDNA Alkylator -
HY-13629
EtoposideTopoisomerase II Inhibitor -
HY-15142
Doxorubicin hydrochlorideTopoisomerase Inhibitor -
HY-17393
CarboplatinDNA Synthesis Inhibitor -
HY-17026
GemcitabineDNA Synthesis Inhibitor -
HY-14519
MethotrexateDihydrofolate Reductase Inhibitor -
HY-N0488
Vincristine sulfateAntineoplastic Agent -
HY-17364
TemozolomideDNA Alkylator -
HY-13669
LomustineDNA Alkylator -
HY-17371
OxaliplatinDNA Synthesis Inhibitor -
HY-13605
CytarabineDNA Synthesis Inhibitor
Publications Citing Use of MedChemExpress (MCE) Ifosfamide
More- Cell Res. 2020 Oct;30(10):833-853. [Abstract]
- Theranostics. 2020 Jul 25;10(21):9477-9494. [Abstract]
- Cell Rep Med. 2025 Apr 15;6(4):102053. [Abstract]
- Cell Death Dis. 2024 May 20;15(5):349. [Abstract]
- J Mol Med (Berl). 2019 Aug;97(8):1183-1193. [Abstract]
- Sci Rep. 2026 Jan 13;16(1):5155. [Abstract]
- J Bone Oncol. 2021 Sep 20:30:100391. [Abstract]
- Breast Cancer Res Treat. 2023 Jul;200(2):193-201. [Abstract]
- Hum Cell. 2025 Jun 2;38(4):115. [Abstract]
- bioRxiv. 2026 Mar 5.
Customer Validation & Images
-
Cell Proliferation/Viability Assay
-
Cell Proliferation/Viability Assay
-
Histological Imaging/Staining
-
Histological Imaging/Staining
-
In Vivo Efficacy Study
Biological Activity
제품 설명
IC50 & Target
DNA Alkylator[1]
In Vitro
Ifosfamide is an alkylating chemotherapeutic agent with activity against a wide range of tumors[1].
Ifosfamide is activated by the cytochrome P450 family. Ifosfamide (0-5 mM) suppresses the viability of CYP2B1-expressing C8III-1 cells, while it is cytotoxic to the non-CYP2B1-expressing CrFK cells only at high concentration (5 mM)[2].
CYP BM3 mutants activates Ifosfamide, and Ifosfamide shows inhibitory activity against human U2OS cells[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 3778-73-2
-
Appearance Solid
-
분자량 261.09
-
화학식 C7H15Cl2N2O2P
-
Color White to off-white
-
SMILES
ClCCN1P(OCCC1)(NCCCl)=O
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications (10)
-
Journal Impact Factor
-
Most Recent
-
Cell Res
Three-dimensional bioprinted glioblastoma microenvironments model cellular dependencies and immune interactions. [Abstract]2020 Oct;30(10):833-853. PMID: 32499560
Ifosfamide purchased from MedChemExpress. Usage Cited in: Cell Res. 2020 Oct;30(10):833-853. [Abstract]
Normalized cell viability of GSCs in tri-culture and tetra-culture models following treatment with 50 μM of ifosfamide.
Ifosfamide purchased from MedChemExpress. Usage Cited in: Cell Res. 2020 Oct;30(10):833-853. [Abstract]
Normalized cell viability of CW468 and 2907 GSCs following treatment with varying doses of ifosfamide (0.1-100 μM) in sphere culture. IC50 values were calculated using a variable slope nonlinear regression model.
Ifosfamide purchased from MedChemExpress. Usage Cited in: Cell Res. 2020 Oct;30(10):833-853. [Abstract]
Bioluminescence imaging of mice bearing subcutaneous glioblastoma tumors derived from CW468 GSCs over a time course of treatment with ifosfamide (80 mg/kg) or vehicle.
Ifosfamide purchased from MedChemExpress. Usage Cited in: Cell Res. 2020 Oct;30(10):833-853. [Abstract]
Normalized bioluminescent signal for each mouse over a time course of treatment with ifosfamide (80 mg/kg) or vehicle. Tumor growth for each mouse was plotted over time and normalized to the day 7 reading. *, p = 0.02. Two way mixed-effects ANOVA was used for statistical analysis.
Ifosfamide purchased from MedChemExpress. Usage Cited in: Cell Res. 2020 Oct;30(10):833-853. [Abstract]
Normalized tumor growth rate per week plotted for each mouse over a time course of treatment with ifosfamide (80 mg/kg) or vehicle. **, p=0.006. Unpaired two-way t-test was used for statistical analysis
-
Theranostics
Molecular signatures of BRCAness analysis identifies PARP inhibitor Niraparib as a novel targeted therapeutic strategy for soft tissue Sarcomas. [Abstract]2020 Jul 25;10(21):9477-9494. PMID: 32863940 -
Cell Rep Med
CAN-Scan: A multi-omic phenotype-driven precision oncology platform identifies prognostic biomarkers of therapy response for colorectal cancer. [Abstract]2025 Apr 15;6(4):102053. PMID: 40187357 -
Cell Death Dis
Deprivation of methionine inhibits osteosarcoma growth and metastasis via C1orf112-mediated regulation of mitochondrial functions. [Abstract]2024 May 20;15(5):349. PMID: 38769167 -
J Mol Med (Berl)
2019 Aug;97(8):1183-1193. PMID: 31201471 -
Sci Rep
Indirubin treatment was associated with modulation of the PI3K/AKT and MAPK pathways and induction of apoptosis and autophagy. [Abstract]2026 Jan 13;16(1):5155. PMID: 41530396 -
J Bone Oncol
Identification of GPC3 mutation and upregulation in a multidrug resistant osteosarcoma and its spheroids as therapeutic target. [Abstract]2021 Sep 20:30:100391. PMID: 34611509 -
Breast Cancer Res Treat
2023 Jul;200(2):193-201. PMID: 37204665 -
Hum Cell
Establishment and comparison of three sublines from a human uterine carcinosarcoma cell line, ESCA. [Abstract]2025 Jun 2;38(4):115. PMID: 40455147 -
용액&용해도
In Vitro:
DMSO : ≥ 125 mg/mL (478.76 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (7.97 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (7.97 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 0.5% CMC-Na/saline water
Solubility: 25 mg/mL (95.75 mM); Clear solution; Need ultrasonic
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
순도&문서
-
Data Sheet (280 KB)
-
SDS (644 KB)
- English - EN (644 KB)
- Français - FR (644 KB)
- Deutsch - DE (644 KB)
- Norwegian - NO (644 KB)
- Español - ES (644 KB)
- Swedish - SV (644 KB)
- Italian - IT (644 KB)
- Korean - KR (644 KB)
- Portuguese - PT (644 KB)
-
Handling Instructions (2659 KB)
References
[1]. Helal M. Prenatal effects of transplacental exposure to ifosfamide in rats. Biotech Histochem. 2016 Jul;91(5):357-68. [Content Brief]
[2]. Karle P, et al. Necrotic, rather than apoptotic, cell death caused by cytochrome P450-activated ifosfamide. Cancer Gene Ther. 2001 Mar;8(3):220-30. [Content Brief]
[3]. Vredenburg G, et al. Activation of the anticancer drugs cyclophosphamide and ifosfamide by cytochrome P450 BM3 mutants. Toxicol Lett. 2015 Jan 5;232(1):182-92. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.8301 mL | 19.1505 mL | 38.3010 mL | 95.7524 mL |
| 5 mM | 0.7660 mL | 3.8301 mL | 7.6602 mL | 19.1505 mL | |
| 10 mM | 0.3830 mL | 1.9150 mL | 3.8301 mL | 9.5752 mL | |
| 15 mM | 0.2553 mL | 1.2767 mL | 2.5534 mL | 6.3835 mL | |
| 20 mM | 0.1915 mL | 0.9575 mL | 1.9150 mL | 4.7876 mL | |
| 25 mM | 0.1532 mL | 0.7660 mL | 1.5320 mL | 3.8301 mL | |
| 30 mM | 0.1277 mL | 0.6383 mL | 1.2767 mL | 3.1917 mL | |
| 40 mM | 0.0958 mL | 0.4788 mL | 0.9575 mL | 2.3938 mL | |
| 50 mM | 0.0766 mL | 0.3830 mL | 0.7660 mL | 1.9150 mL | |
| 60 mM | 0.0638 mL | 0.3192 mL | 0.6383 mL | 1.5959 mL | |
| 80 mM | 0.0479 mL | 0.2394 mL | 0.4788 mL | 1.1969 mL | |
| 100 mM | 0.0383 mL | 0.1915 mL | 0.3830 mL | 0.9575 mL |
Ifosfamide Related Classifications
HY-17419 Related Classifications
Powered by Bioz